L-selectin has been suggested to play a role in the pathogenesis of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis. Here we demonstrate that L-selectin -/-SJL mice are susceptible to proteolipid protein (PLP)-induced EAE because the compromised antigen-specific T cell proliferation in peripheral lymph nodes is fully compensated by the T cell response raised in their spleen. Transfer of PLPspecific T cells into syngeneic recipients induced EAE independent of the presence or absence of L-selectin on PLP-specific T cells or in the recipient. Leukocyte infiltration into the central nervous system parenchyma was detectable independent of the mode of disease induction and the presence or absence of L-selectin. In addition, we found L-selectin -/-C57BL/6 mice to be susceptible to myelin oligodendrocyte glycoprotein-induced EAE. Taken together, we demonstrate that in SJL and C57BL/6 mice L-selectin is not required for EAE pathogenesis. The apparent discrepancy of our present observation to previous findings, demonstrating a role of L-selectin in EAE pathogenesis in C57BL/6 mice or myelin-basic protein (MBP)-specific TCR-transgenic B10.PL mice, may be attributed to background genes rather than L-selectin and to a unique role of L-selectin in EAE pathogenesis in MBP-TCRtransgenic mice.
Introduction
In multiple sclerosis (MS), and in its animal model, experimental autoimmune encephalomyelitis (EAE), circulating immune cells gain access to the CNS and cause inflammation, blood-brain barrier (BBB) breakdown and demyelination, all of which set the stage for the development of the clinical manifestations of this disabling disease. EAE is a T cell-mediated autoimmune disease, which can be either actively induced (aEAE) by immunization with myelin antigens or by the transfer of encephalitogenic myelinspecific T cells in susceptible rodents including several mouse strains. In the SJL mouse, EAE is mostly induced by immunization with a proteolipid protein (PLP) peptide (amino acids 139-151, PLP aa139-151 ) or the adoptive transfer of the respective PLP-specific CD4 + T cell blasts into syngeneic recipients. Similarly, in the C57BL/6 mouse, EAE is most commonly induced by immunization with a myelin oligodendrocyte glycoprotein (MOG) peptide (amino acids 35-55, MOG aa35-55 ) or by the adoptive transfer of the respective MOG-specific CD4 + T cell blasts into -usually sublethally irradiated -syngeneic recipients. Interaction of circulating immunocompetent cells with the BBB endothelium is a critical step in the pathogenesis of CNS inflammation during EAE.
The recruitment of specific leukocyte subsets from the blood stream into distinct tissues is mediated by the sequential interaction of different adhesion and signaling molecules on leukocytes and the endothelial cells lining the vessel wall (reviewed by [1] ). The multi-step interaction starts with an initial transient contact of the circulating leukocyte with the vascular endothelium, mediated by adhesion molecules of the selectin family and their respective carbohydrate ligands, or by a4 integrins. After the initial tether, the leukocyte rolls along the vascular wall with greatly reduced velocity. The rolling leukocyte can then bind chemotactic factors from the family of chemokines presented on the endothelial surface. Chemokines bind to serpentine receptors on the leukocyte surface delivering a G protein-mediated inside-out signal to integrins present on the leukocyte surface, thereby enhancing their avidity. Only integrins with increased avidity are able to mediate the firm adhesion of the leukocytes to the vascular endothelium by binding to their endothelial ligands of the immunoglobulin (Ig) superfamily. This ultimately leads to diapedesis of the leukocyte.
It is generally accepted that a4 integrins play a predominant role in T cell trafficking across the BBB during EAE, as they mediate both T cell rolling and firm adhesion of T cells to the BBB (summarized in [2] ). In contrast, the adhesion molecules generally mediating leukocyte rolling along the vascular wall, such as P-selectin glycoprotein ligand (PSGL-1) [3, 4] or its endothelial ligands E-and P-selectin, are not required for the development of EAE in C57BL/6 and SJL mice [5, 6] . Similarly, L-selectin has been shown in antibody blocking experiments to play no role in the recruitment of inflammatory cells across the BBB during EAE [7] ; nevertheless, its role in EAE pathogenesis remains controversial [8, 9] .
L-selectin was first described as the peripheral lymph node (PLN)-homing receptor, defined by the mAb Mel 14, which blocks T cell rolling on high endothelial venules in PLN [10, 11] . Later, it was discovered that L-selectin is expressed on almost all leukocyte subpopulations including neutrophils and monocytes/macrophages. Thus, besides its role in immunosurveillance, L-selectin has been shown to mediate inflammatory cell recruitment to a variety of sites of inflammation (summarized in [12] ). In addition, studies performed in L-selectin-deficient mice have demonstrated an involvement of L-selectin in the generation of primary T cell responses [13, 14] , suggesting a potential role of L-selectin in the development of autoimmune diseases.
As mentioned above, investigations on the role of L-selectin in EAE pathogenesis have produced controversial results. Antibody inhibition studies performed in passive transfer EAE models in the Lewis rat or the (PLxSJL)F 1 mouse failed to demonstrate any role of L-selectin in EAE pathogenesis [7, 15] . In contrast, anti-Lselectin antibodies block the development of aEAE in the Lewis rat [15] . Furthermore, L-selectin-deficient C57BL/6 mice were reported to be resistant to EAE due to the failure of encephalitogenic T cell priming [8] , whereas L-selectin-deficient myelin-basic protein (MBP)-specific TCR transgenic B10.PL mice failed to develop clinical EAE due to a requirement of L-selectin for effector functions of CNS inflammatory cells [9] .
To obtain more insight into the role of L-selectin in EAE pathogenesis we decided to investigate its role in EAE pathogenesis in the SJL mouse model, which allows both the induction of active EAE by immunization with myelin antigen and adoptive transfer of EAE with PLP-specific CD4 + T cells without further manipulation of the mice such as sublethal irradiation as required in the C57BL/6 mouse model. Furthermore, studies in the SJL EAE models have allowed the definition of the role of a4 integrins in inflammatory cell trafficking across the BBB [16, 17] , a finding that has been translated into a novel therapy for relapsingremitting MS with the anti-a4 integrin antibody natalizumab. We have backcrossed L-selectin-deficient mice for at least 11 and up to 18 generations into the SJL background. Here, we show that L-selectin -/-SJL mice are neither resistant to active EAE induced by immunization with PLP aa139-151 nor to EAE passively transferred by PLP-specific T cells. Furthermore, L-selectin is not required on PLP-specific T cells to transfer EAE or on inflammatory cells to enter the CNS parenchyma. Additionally, we have backcrossed L-selectin-deficient mice for 18 generations into the C57BL/6 background and found that these mice are susceptible to EAE. Thus, in the C57BL/6 as in the SJL mouse L-selectin is neither required for immune cell trafficking to the CNS nor for the priming, clonal expansion and effector function of encephalitogenic T cells. Our results suggest that the previously reported role of L-selectin in establishing clinical EAE is unique to MBP-TCR B10.PL mice [9] and that sufficient backcrossing is required to be able to distinguish a role of L-selectin from that of other mouse background genes in EAE pathogenesis.
Results

Anti-L-selectin antibody Mel-14 does not inhibit aEAE in the SJL mouse
It has been reported that anti-L-selectin antibodies block aEAE, but fail to inhibit adoptively transferred EAE. Antibody inhibition studies were performed to test whether treatment of SJL mice with the anti-L-selectin antibody Mel-14 blocks aEAE induced by immunization of SJL mice with PLP aa139-151 in CFA. Interestingly, despite detectable serum levels of the antibody, Mel-14 failed to exert any influence on the development of aEAE in the SJL mouse model ( Table 1) .
Characterization of L-selectin-deficient SJL mice
As L-selectin-deficient MBP-specific TCR transgenic B10.PL mice and L-selectin-deficient C57BL/6 mice are reported to be resistant to EAE [8, 9] , we anticipated that development of EAE might only be impaired in the complete absence of L-selectin. L-selectindeficient mice were therefore backcrossed to the EAE-susceptible genetic background of the SJL strain for at least 11 generations before being analyzed and used in the experiments described. To ascertain that the phenotype of L-selectin-deficient mice described in the 129/Sv//C57BL/6 chimeric genetic background [14] is maintained in the SJL background, lymphoid organ architecture was investigated by immunohistochemistry and lymphocyte numbers were determined. Reproducing the phenotype published for L-selectin -/mice in the chimeric background [14] , mesenteric lymph nodes (MLN) of L-selectin -/-SJL mice were found to resemble those of wild-type mice (data not shown and Table 2 ). As reported previously, PLN, i.e., popliteal, inguinal, para-aortical, axillary and cervical LN, were strikingly smaller in size (data not shown) and significantly depleted for lymphocytes ( Table 2 ). In contrast, the spleens of L-selectin -/-SJL mice were enlarged and harbored a significantly increased number of lymphocytes, when compared to wild type SJL mice (Table 2) . Additionally, L-selectin deficiency in the SJL background lead to an apparently increased number of lymphocytes circulating in the blood stream when compared to wild-type SJL mice, which was found to be not significant ( Table 2 ). To address, whether lack of L-selectin expression affects the cell surface expression of adhesion molecules that have previously been demonstrated to be involved in EAE pathogenesis, we investigated the surface expression of a4b1and a4b7-integrin and LFA-1 on T lymphocytes isolated from MLN and PLN as well as the spleen. We did not detect any significant differences between wild-type SJL and L-selectin -/-SJL mice (data not shown).
L-selectin deficient SJL mice develop EAE upon adoptive transfer with wild-type PLP-specific T cells
We next asked whether the transfer of PLP-specific CD4 + T cells can elicit EAE in L-selectin -/-SJL mice, as the observations reported in the L-selectin-deficient MBP-TCR transgenic B10.PL mouse and C57BL/6 mouse EAE models are contradictory in this issue [8, 9] . The transfer of freshly activated encephalitogenic T cells from PLP-specific CD4 + Th1 cell lines induced EAE in L-selectin -/-SJL mice in a manner indistinguishable from wildtype SJL mice ( Fig. 1 ). Furthermore, we did not observe any difference in the size and cellular composition (CD3 + T cells, B220 + B cells, Mac-1 + macrophages, CD4 + T cells) of the inflammatory cuffs in frozen sections of brains and spinal cords of wild-type and L-selectin -/-SJL mice during EAE. Thus, expression of L-selectin in the host is not required for the development of clinical EAE in SJL mice. Mean severity of disease 2.6 AE 1.5 2.5 AE 1.8 a) Antibody, 400 lg, was injected i.v. at day -1 before induction of EAE and at days 4 and 10 after induction of EAE. Presence of saturating antibody titers was confirmed by FACS analysis on PLN lymphocytes. One representative experiment out of three is shown. 
Encephalitogenic T cells up-regulate L-selectin expression in vivo
It has been reported that encephalitogenic T cells change their surface phenotype in vivo [18] . Thus, although encephalitogenic T cell blasts transferring EAE do not display any cell surface expression of L-selectin in vitro ( Fig. 2) , they might up-regulate expression of L-selectin in vivo. L-selectin could thus still be required on encephalitogenic effector T cells to successfully transfer EAE into syngeneic recipients. To address this, CellTracker TM Green-labeled encephalitogenic T cell blasts were intravenously injected into SJL mice and at 48 and 72 h after injection spleen, MLN and PLN were harvested and cell suspensions were stained with Mel-14 to detect surface expression of L-selectin. Due to the low number of encephalitogenic T cells homing to the brain and spinal cord early after injection, cell surface expression of L-selectin on the injected encephalitogenic T cells from these organs could not be determined. However, L-selectin expression could clearly be detected on a low percentage of CellTracker TM Green-stained encephalitogenic T cells present in the different secondary lymphoid organs already 48 h after infusion. By 72 h after infusion all CellTracker TM Green-positive encephalitogenic T cells present in PLN and significant subpopulations of these T cells present in MLN and the spleen stained positive for L-selectin ( Fig. 2 ). PLP-specific T cells grown in vitro remained negative for L-selectin cell surface staining throughout this time (not shown).
Thus, in vivo a subpopulation of encephalitogenic T cells originating from the transferred T cells up-regulates L-selectin cell surface expression. Therefore, L-selectin could indeed contribute to their effector functions required for establishing clinical EAE.
L-selectin-deficient SJL mice develop active EAE
To study whether EAE can develop in the complete absence of L-selectin, we next asked, if EAE can be actively induced in L-selectin -/-SJL mice. Interestingly, we did not observe any difference in the onset, duration or clinical severity of aEAE in L-selectin -/-SJL mice in backcrossing generations N16-N18 when compared to wild-type control mice ( Fig. 3 ). Thus, in the SJL background L-selectin is not required for the in vivo priming of encephalitogenic T cells, their trafficking to the CNS or the subsequent molecular mechanisms involved in CNS tissue damage, which all contribute to establish the clinical picture of EAE.
PLP-specific T cells are primed in the spleen of L-selectin -/-SJL mice
As L-selectin -/-SJL mice have dramatically reduced PLN, we next aimed to determine, where PLP-specific T cells are primed in Figure 2 . L-selectin is up-regulated on encephalitogenic PLP-specific T cells in vivo. SJL.PLP6 lymphoblasts were labeled with CellTracker TM Green directly after restimulation and intravenously injected into SJL mice. In parallel, a small subset of labeled T cells was cultured in vitro to confirm stability of CellTracker TM labeling and cell surface phenotype. 48 (day 2) and 72 (day 3) h after injection splenocytes, MLN and PLN cells were harvested and stained for L-selectin using the mAb Mel-14.
Cells were scatter gated for live and green fluorescent cells. In contrast to in vitro grown SJL.PLP6, which stained negative for L-selectin, L-selectin expression can be detected on CellTracker TM -positive SJL.PLP6 cells present in spleen, MLN and PLN starting at 2 days after injection. Isotype control staining is shown by a dotted line. One of two independent experiments is shown. L-selectin -/versus wild-type SJL mice in vivo after subcutaneous immunization with PLP aa139-151 in CFA. We performed in vitro antigen-recall proliferation assays with lymphocytes isolated from draining PLN, spleen and blood. In SJL wild-type mice, a prominent T cell proliferation response to PLP aa139-151 was detected at 6 days after immunization in the draining PLN and to a lesser degree in the spleen and the blood (Fig. 4 ). In contrast, in L-selectin -/-SJL mice, the PLP aa139-151 -specific T cell proliferation was limited to the spleen and maintained there at a comparable level to wild-type mice until the beginning of the disease (day 10 post immunization, p.i.) and during clinical EAE (day 14 p.i.). Although a detectable PLP-specific T cell response is mounted in the PLN of L-selectin -/-SJL mice in parallel to the onset of clinical EAE, it remained significantly lower than that observed in PLN of wild-type SJL mice ( Fig. 4) . To test if the reduced PLP-specific T cell proliferation observed in PLN of L-selectin -/-SJL mice is due to a general proliferation defect of L-selectin-deficient T lymphocytes, we tested their proliferation to polyclonal stimuli such as Con A and anti-CD3/anti-CD28 stimulation and did not observe any significant difference (data not shown). Once clinical EAE started (day 10 p.i.), a comparable number of PLP-specific T cells was observed in the peripheral blood of both wild-type and L-selectin -/-SJL mice. Thus, in L-selectin -/-SJL mice, PLP-specific T cells are predominantly primed in the spleen and later and to a lesser degree in the PLN. Nonetheless, these T cells travel to the CNS at the same time as in wild-type mice since they can be detected in identical amounts in the peripheral blood. Ovalbumin-specific T cells are primed in the spleen of L-selectin -/-SJL mice
It has been shown that SJL mice harbor a high frequency of PLP aa139-151 -specific T cells due to their escape from central tolerance, as intrathymic expression of PLP is restricted to the shorter splice variant DM20 [19, 20] . Thus, specifically in SJL mice, lack of L-selectin might have less impact on the priming of encephalitogenic PLP aa139-151 -specific T cells as compared to the priming of T cells with other antigen-specificities. We therefore immunized L-selectin-deficient SJL mice and wild-type SJL mice subcutaneously with the model antigen OVA in CFA and compared the in vitro antigen-recall proliferation of OVA-specific T lymphocytes isolated from the draining PLN and the spleen. Similar to our observations made after immunization with PLP aa139-151 , SJL wild-type mice exhibited a prominent OVAspecific T cell proliferative response in the draining PLN and to a lesser degree in the spleen already at 6 days p.i. (Fig. 5 ). In both secondary lymphoid organs the OVA-specific T cell response further increased at 10 and 14 days p.i. in SJL wild-type mice. In L-selectin -/-SJL mice, a significantly reduced OVA-specific T cell proliferation was measured in the PLN and the spleen 6 days after immunization. However, also in L-selectin -/-SJL mice the OVAspecific T cell proliferation was found to be increased at 10 and 14 days p.i., reaching comparable levels to the OVA-specific T cell proliferation in SJL wild-type mice. Thus, in L-selectin -/-SJL mice, priming to a subcutaneously applied model antigen is not generally impaired but rather leads to a compensatory shift of antigen-specific T cell priming to the enlarged spleens of these mice when compared to SJL wild-type mice.
L-selectin deficient PLP-specific T cells transfer EAE into wild-type and knockout mice
After identifying the spleen as the immune organ, where antigenspecific T cells are primed in L-selectin -/-SJL mice, we set out to investigate whether L-selectin -/-PLP-specific T cell blasts can transfer EAE into wild-type and L-selectin -/-SJL mice. We isolated splenocytes from L-selectin -/-SJL mice subcutaneously immunized with PLP aa139-151 in CFA 10 days earlier. These were activated with their specific antigen for 4 days in vitro, and 1 Â 10 7 PLP-specific T cell blasts (Fig. 6A) were then intravenously injected into syngeneic wild-type and L-selectin -/mice. L-selectin -/-PLP-specific T cells were found to transfer EAE to both wild-type SJL and L-selectin -/-SJL mice (Fig. 6B ). We did not observe any significant difference in the onset, severity or duration of disease. Thus, effector T cells do not require L-selectin to transfer EAE in the SJL mouse.
L-selectin is not required for inflammatory cell entry into the CNS parenchyma during EAE in the SJL mouse
Perivascular infiltrates in the brains and spinal cords of EAEresistant L-selectin -/-MBP-TCR transgenic B10.PL mice were found to be restricted to the perivascular space, suggesting that in this model L-selectin is required for extravasation of inflammatory cells across the glia limitans into the CNS parenchyma [9] . We therefore investigated the localization of CD45 + inflammatory cells in the brains of wild-type and L-selectin -/-SJL mice during clinical EAE induced either by the transfer of wild-type or L-selectin-deficient PLP-specific T cells. Performing double immunofluorescence staining on frozen brain sections of these mice suffering from EAE demonstrated that independent of the absence or presence of L-selectin on the encephalitogenic T cells or in the host, CD45 + inflammatory cells were able to leave the perivascular space marked by laminin-positive borders (Fig. 7) . Furthermore, we did not observe any difference in the size and cellular composition (CD3 + T cells, B220 + B cells, Mac-1 + macrophages, CD4 + T cells) of the inflammatory cuffs in the brains of wild-type and L-selectin -/-SJL mice during clinical EAE induced either by the transfer of wild-type or L-selectin-deficient PLP-specific T cells (data not shown). Thus, in SJL mice, L-selectin is neither required for inflammatory cell migration across the endothelial BBB nor for their immigration into the CNS parenchyma. 
L-selectin-deficient C57BL/6 mice develop active EAE
Based on our present findings that L-selectin is not required for the priming, clonal expansion and effector function of encephalitogenic T cells during EAE in SJL mice, the previous observations that L-selectin-deficient C57BL/6 mice are resistant to EAE due to their failure to mount an encephalitogenic T cells response is quite surprising. Resistance to EAE was observed in L-selectin-deficient C57BL/6 mice in backcrossing generation N10 [8] . To find out whether more extensive backcrossing of L-selectin-deficient mice into the C57BL/6 background, as performed by us for the SJL mice, has any influence on EAE development, we investigated the development of MOG-induced EAE in L-selectin -/-C57BL/6 mice in backcrossing generation N18. Interestingly, we found that L-selectin -/-C57BL/6 mice were susceptible to MOG-induced active EAE (Fig. 8) , demonstrating that L-selectin -/-C57BL/6 mice in N18 can mount an encephalitogenic T cell response in the absence of L-selectin.
Discussion
In this study we demonstrate that the lack of L-selectin does not confer resistance to EAE in the SJL mouse. Our studies with L-selectin -/-SJL mice demonstrate that in this model L-selectin is not required for the priming, clonal expansion or effector function of encephalitogenic T cells, or for inflammatory cell trafficking across the BBB and into the CNS parenchyma during EAE. Transfer EAE studies with wild-type and L-selectin -/-SJL mice as recipients, and wild-type and L-selectin -/-PLP-specific T cell lines, confirmed that L-selectin is not needed on encephalitogenic T cells or in the syngeneic recipient for the development of the full clinical and histopathological picture of EAE. Antibody inhibition studies with the anti-L-selectin antibody Mel-14 performed in PLP aa139-151induced EAE in the SJL wild-type mouse failed to interfere with the clinical development of EAE, and thus confirm the observations made in the L-selectin -/-SJL mouse. Finally, L-selectin -/-C57BL/6 mice in backcrossing generation N18 were found to be susceptible to EAE. Our observations are in apparent contrast to those made in the Lewis rat EAE model, where anti-L-selectin antibodies were shown to suppress EAE induced by immunization with MBP [15] . Interestingly, the very same study demonstrated that anti-Lselectin antibodies do not interfere with EAE induced by the adoptive transfer of encephalitogenic T cells [15] , suggesting that blocking of L-selectin in this EAE model targets priming of encephalitogenic T cells in vivo rather than T cell trafficking into the CNS. A lack of involvement of L-selectin in T cell migration across the BBB is supported by the findings that Mel-14 does not inhibit the development of clinical EAE induced by transfer of PLPspecific T cells into (PLxSJL)F 1 mice due to its failure to block T cell homing to the CNS [7] . The finding that lack of L-selectin does not prevent leukocyte trafficking across the endothelial BBB in general is further supported by active EAE studies performed in MBP-TCR transgenic B10.PL mice [9] . Although B10.PL mice on a L-selectin null background are resistant to clinical EAE, inflammatory cells were still found to accumulate in the brains and spinal cords of these mice after immunization with MBP. Thus, all EAE models investigated have produced evidence that L-selectin is not required for immune cell migration across the BBB.
Interestingly, the perivascular infiltrates observed in the brains and spinal cords of the L-selectin -/-MBP-TCR transgenic B10.PL mice [9] remain clinically silent. Such clinically silent perivascular infiltrates limited by the endothelial and the parenchymal basement membranes have been observed before in EAE studies Figure 7 . CNS parenchymal infiltration by CD45 + inflammatory cells during EAE is independent of the presence of L-selectin on encephalitogenic T cells or in the host. Double immunofluorescence staining for CD45 (green) and laminin (red) of frozen brain sections from mice with EAE are shown. Staining demonstrates that the presence of CD45 + inflammatory cells outside of the laminin-bordered perivascular space is independent of the transfer of EAE by either wild-type (SJL. PLP57) or L-selectin-deficient (SJL/L-Sel.PLP20) PLP-specific T cells and is also independent of the presence or absence of L-selectin within the host. Bar 50 lm. performed in C57BL/6 mice deficient for matrix metalloproteinases-2 and -9 [21] or for TNF-a [22] and also in the SJL mouse EAE model after depletion of macrophages [23] . In this context it is remarkable that clinical EAE could be induced in the L-selectin -/-MBP-TCR transgenic B10.PL mice by the adoptive transfer of wild-type macrophages [9] , and F4/80 + macrophages could then be detected in the CNS parenchyma of these mice. As neither the activation of MPB-specific T cells nor inflammatory cell recruitment across the endothelial BBB was impaired in the MBP-TCR transgenic L-selectin -/-B10.PL mice, these observations suggest an involvement of L-selectin in macrophage extravasation to the CNS parenchyma and/or the destruction of myelin during the effector phase of EAE. In this context it is important to note that CNS myelin harbors not-yet-defined L-selectin ligands, which mediate lymphocyte binding in vitro [24, 25] . The necessity of L-selectin engagement of a myelin ligand as a prerequisite for the development of clinical EAE could, however, neither be observed in L-selectin -/-SJL mice in the present study nor in L-selectin -/-C57Bl/6 mice [8] . In the latter study performed in the C67BL/6 model it was found that MOG-specific T cells transfer EAE into sublethally irradiated syngeneic recipients independent of the presence or absence of L-selectin on the encephalitogenic T cells or the recipient [8] . These observations are in accordance to those made by us in the SJL mouse, where we did not find any difference in the development of EAE transferred by PLP-specific T cells into syngeneic recipients irrespective of the presence or absence of L-selectin on PLP-specific T cells or in the recipient. A requisite role of L-selectin on macrophages for invasion of the CNS parenchyma during EAE and to mediate myelin damage was thus only observed in MBP-TCR transgenic B10.PL mice, but could not be validated in EAE studies performed in L-selectin -/-C57Bl/6 or SJL mice. A requirement of L-selectin for the development of clinical EAE may thus be a unique feature of the MBP-TCR transgenic B10.PL mouse model, where monoclonal myelin-specific T cell activation might overemphasize a role for L-selectin in triggering the effector function of macrophages required to establish clinical EAE.
Due to their lymphocyte homing defect, L-selectin -/mice have dramatically reduced PLN irrespective of their inbred strain background. Thus, an impaired or delayed priming of encephalitogenic T cells upon induction of active EAE by subcutaneous immunization with myelin antigens in CFA is expected. Surprisingly, L-selectin -/-SJL mice in backcrossing generations N11-N18 did not show any difference in the clinical development of aEAE when compared to wild-type SJL mice. Nevertheless, we found that L-selectin deficiency does indeed compromise the priming of both PLP-and OVA-specific T cells in the PLN. In contrast, antigenspecific T cell proliferation in the spleens of L-selectin -/-SJL mice is not affected. Independent of the organ location of their priming, PLP-specific T cells were then detectable in equal amounts in the peripheral blood of both wild-type and L-selectin -/-SJL mice at day 10 p.i. right before disease onset. Thus, in the L-selectin -/-SJL mouse there is a compensatory shift of PLP-specific T cell priming from PLN to the enlarged spleens, resulting in the lack of any impact on EAE development. Interestingly, in the MBP-TCR B10.PL mice, T cell priming upon immunization with MBP was found to be generally unaffected on the L-selectin -/background in both the spleen but also the PLN [9] . This surprising finding might be due to the unphysiologically high numbers of antigen-specific T cells already pre-existing in the extremely small PLN of L-selectin -/-MBP-TCR transgenic B10.PL mice. This assumption is supported by the observation that, similar to our observations made in L-selectin -/-SJL mice, L-selectin -/-C57BL/6 mice demonstrate a profound defect in the priming of myelin-specific T cells in the PLN upon induction of active EAE [8] . In contrast to our findings, L-selectin -/-C57BL/6 mice in backcrossing generations N10 were previously reported to be fully resistant to the induction of active EAE due to their complete failure to mount a MOG-specific T cell response in both the PLN and the spleen [8] . Using L-selectin -/-C57BL/6 mice more extensively backcrossed to the C57BL/6 background (N18), we have found these mice to be quite susceptible to the development of aEAE. Our observations in L-selectin -/-C57BL/6 mice (N18) are quite analogous to those in L-selectin -/-SJL mice, where, upon extensive backcrossing (N11-N18), susceptibility of EAE mirrors that of control SJL mice. The apparent discrepancy in susceptibility to EAE in L-selectin -/-C57BL/6 mice in the previous study compared to our present investigation may thus be attributable to the further backcrossing, subtleties in the EAE induction process, animal housing or other factors.
Taken together, our findings and those by others are in agreement regarding that L-selectin is not required for immune cell migration across the BBB during EAE, irrespective of the EAE model investigated. In the SJL mouse, lack of L-selectin has no impact on the priming, clonal expansion and effector function of encephalitogenic T cells and the development of active or passive EAE. Formally it cannot be excluded that the observed involvement of L-selectin in EAE pathogenesis is due to a closely linked genetic locus modifying L-selectin activity, which could not be separated by backcrossing for 6 or 10 generations as performed in the previous studies. Our observations demonstrating EAE susceptibility of L-selectin -/-C67BL/6 mice in backcrossing generation N18 support the notion that in higher backcrossing generations absence of L-selectin does not confer protection to aEAE. Finally, it will be important and quite valuable for the interpretation of results obtained in related experimental strategies to find out whether the involvement of L-selectin in triggering effector functions of CNS macrophages during EAE is a unique requirement only observable in an EAE model investigating TCR-transgenic mice.
Material and methods
Mice
All animal procedures were performed in accordance with the Swiss and the US legislation on the protection of animals and approved by the respective government authorities. SJL mice were obtained from Taconic (Bomholt, Denmark) and Harlan Winkelmann (Horst, The Netherlands), C57BL/6 mice from Jackson Laboratories (Bar Harbor, ME). L-selectin-deficient mice [14] were backcrossed into the EAE susceptible SJL background and used for analysis starting from the 11th backcrossing generation. Most experiments shown in the manuscript were performed with SJL mice in backcrossing generations N15-N18. L-selectin -/-C57BL/6 mice were used in backcrossing generation N18.
Genotyping of mice
The genotype of mice was confirmed by PCR from tail biopsies before and after the experiments. PCR were performed on a Mastercycler ep gradient S (Vaudaux-Eppendorf, Schönenbuch, Switzerland) in 20-lL reactions with primers at 0.65 lM each, dNTP at 0.2 mM, 1 U Taq polymerase (Promega) containing 1 lL proteinase K-treated lysates from tail biopsies. PCR cycling was always preceded by a 4-min denaturation step at 94 C and followed by a 10-min final extension step at 72 C.
Wild type: FW1 5 0 -TGC CTG GTC CTA GAA CAC TC-3 0 , Rev1 5 0 -GTG GTC CCA CAT CAG CGT AG-3 0 ; PGKneo: FW2 5 0 -TGT GCC TGG TCC TAG AAC ACT C-3 0 , PGK-Rev2 5 0 -TGT CAC GTC CTG CAC GAC GC-3 0 . PCR was conducted for 35 cycles of 45 s. at 94 C, 45 s at 60 C, 60 s at 72 C. The resulting PCR products are 480 bp in size for the wild-type allele and 596 bp for the PGK neo allele.
Primers Tie1-FW3 (5 0 -CGA AGG GAT GGG AGA GAG AGC-3 0 ) and Tie1-Rev2 (5 0 -TGA CGC TAT GAC GAC GAC GAT G-3 0 ) were included in the amplification of an internal control product from the mouse Tie-1 gene.
Peripheral blood and LN lymphocyte counts
Mice were killed, blood was collected and draining LN and spleen were removed. Single-cell suspensions were produced and cell numbers were determined using the CASY TT Cell counter (Schärfe System, Reutlingen, Germany).
Antibodies
Anti-mouse CD28 and FITC-conjugated CD45 were purchased from BD Pharmingen (Basel, Switzerland); anti-mouse CD3e was purchased from Milan Analytica AG (La Roche, Switzerland). MEC13.3 (anti-mouse PECAM-1) was a kind gift of Dr. E. Dejana (Milano, Italy). Supernatants of the hybridomas Hermes-1 (9B5, anti-human CD44, used as an isotype-matched control), Mel-14 (anti-L-selectin), M1/9 (anti-mouse CD45), M1/70 (anti-mouse Mac-1), and GK1.5 (anti-mouse CD4) were produced in our own laboratory and used undiluted. For in vivo use endotoxin free antibody preparations were obtained from serum free culture medium by ammonium sulfate precipitation as described before [16] . Polyclonal rabbit anti-laminin antibody (used at 1:200 in immunofluorescence) and rabbit anti-human von Willebrand-Factor (vWF) antibody (used at 1:800 in immunofluorescence) were purchased from Dako Diagnostic AG (Zug, Switzerland).
Immunohistology and immunofluorescence
Mice were anesthetized with isoflurane (Baxter, Arovet AG, Zollikon, Switzerland) and perfused with 1% paraformaldehyde (Grogg Chemie AG, Stettlen/Deisswil, Switzerland) in PBS through the left ventricle of the heart. Brains and spinal cords were removed, embedded in Tissue-Tek (OCT compound, Haslab, Ostermundingen, Switzerland), snap frozen in an isopentane/dry ice bath (Grogg Chemie AG) and stored at -80 C. For immunohistology, cryostat sections (6 lm) were air-dried overnight, acetone fixed and stained using a three-step immunoperoxidase staining kit (Vectastain, Reactolab SA, Servion, Switzerland) according to the manufacturer's protocol exactly as described before [3] . For immunofluorescence staining, sections were blocked for 20 min with skimmed milk, incubated for 1 h each with primary and secondary antibody diluted in skimmed milk, with Tris-buffered saline (TBS) washing steps in between. After a final TBS wash, sections were mounted in Mowiol (Calbiochem, Grogg Chemie AG).
Induction of EAE in SJL mice
Active EAE was induced by immunizing 8-12-week-old female wild-type and L-selectin-deficient SJL mice with 50 lg PLP aa139-151 in complete Freund's adjuvant (Santa Cruz, LabForce, Nunningen, Switzerland) supplemented with 4 mg/mL nonviable, desiccated Mycobacterium tuberculosis (H37RA, Difco BD Bioscience Clontech, Allschwill, Switzerland) subcutaneously exactly as described [6] . Per mouse, 3 Â 10 9 attenuated Bordetella pertussis organisms (kindly provided by Crucell-Berna Biotech AG, Bern, Switzerland) were administered intravenously in 0.1 mL PBS at days 1 and 3 p.i. Passively transferred EAE was induced in SJL mice by intravenous injection of 3 Â 10 6 freshly activated syngeneic encephalitogenic CD4 + PLP-specific T cells or as indicated for the individual experiments [5, 16] . The PLP-specific Th1 memory/effector T cell lines SJL.PLP2 to SJL.PLP9 raised against the PLP peptide aa139-151 have been described in detail before [16, 26] . In agreement with the requirement of the local government, assessment of clinical disease activity was performed twice daily as described before [6] by documenting the clinical severity EAE using a four-point-scoring system as follows: 0, healthy; 0.5, limp tail; 1, hind leg paraparesis; 2, hind leg paraplegia; and 3, hind leg paraplegia with incontinence. Note that at clinical score 2 mice are still motile, whereas at clinical score 3 motility of animals begins to be impaired. Additionally, in the SJL EAE model we documented the weight changes during the disease course as we have found this to be a valuable additional measure for disease activity.
